After 33 Years of Failure to Produce Any Vaccine Novavax Targets Children for COVID-19 Vaccine
by Brian Shilhavy
Editor, Health Impact News
Ben Adams of FiercePharma, the marketing trade publication for the pharmaceutical industry, just published an article today announcing that Novavax has unveiled a new “education campaign” for its COVID-19 vaccine that is expected to get an EUA (emergency use authorization) from the FDA soon.
[…]
In reading this press release at FiercePharma today, I found it rather remarkable that they are admitting that the mRNA COVID-19 vaccines are actually dangerous for children, something the FDA and CDC refuse to acknowledge, as they position Novavax as a better alternative for children.
Pfizer, Moderna and Johnson & Johnson were quickest off the mark in getting COVID vaccines into American arms, but Novavax is hoping to add another pandemic vaccine to the U.S. mix soon—and it’s pushing new campaigns to get the word out.
The biopharma, which has approvals and authorizations in Europe and around the world, is now on the cusp of a potential green light in the U.S. And with a market comes the need for marketing.
But because it still has no U.S. approval—and it cannot under law advertise to consumers in Europe—Novavax is launching two new global, unbranded vaccine education programs: “We Do Vaccines” and “Know Our Vax.” They’re designed to offer up vaccine information and “explain Novavax’ commitment to vaccine development and innovation,” the company told Fierce Pharma Marketing.
The main message of the campaign is that “people have options when it comes to their vaccine,” Silvia Taylor, senior vice president of global corporate affairs at Novavax, said in an interview. “We want people to understand that we have this vaccine, and that this vaccine is different.”
Novavax knows it has some tough competition—Pfizer and Moderna’s vaccines dominate the U.S. market—but the small biotech is eyeing certain market niches: The “vaccine hesitant” who might be leery of the brand-new mRNA tech in Pfizer and Moderna’s shots, and children.
The vaccine contains a version of the SARS-CoV-2 spike protein made in the lab as well as an adjuvant, which is a booster ingredient designed to strengthen immune responses to the vaccine.
Novavax is also targeting the pediatric population. There are questions about how well mRNA vaccines work in younger children. There are also safety concerns, notably the rates of myocarditis in young and adolescent boys, who appear to be more at risk from this condition, which can cause dangerous inflammation of the heart.
Taylor believes Nuvaxovid can be a safe and efficacious second choice for children and adolescents outside of mRNA. (Full article.)
I had been led to believe in the past that Novavax was a new company that had never produced a single vaccine, but I dug a bit deeper today and learned that they have actually been around for over 33 years, and have had multiple failures in trying to produce any vaccine at all in the past.
I found an article that was published in some UK publications earlier this month, and here is one that is not behind a paywall:
Novavax closes in on Covid triumph after 33 years of failure
Less than a year before the Covid-19 pandemic ravaged the world, Novavax was facing delisting from the Nasdaq. The pharmaceutical company had poured hundreds of millions of dollars into research and development for vaccines — and yet, at 33 years old, was approaching middle age without a single approved shot.
[…]
So how does a company with a 33-year track record of failure, even after receiving an $89 million research grant from the Bill and Melinda Gates Foundation in 2015, and then another $384 million from the Coalition for Epidemic Preparedness Innovations in 2020, which is also funded by Bill Gates, get to the point where it introduces its first vaccine for the COVID-19 “virus”?
The same way that Pfizer and Moderna were able to introduce an mRNA vaccine into the market after decades of failing to get an mRNA vaccine approved for HIV/AIDS:
Have President Trump’s administration declare a “pandemic” so that the FDA can start handing out EUAs to Big Pharma to resurrect these old vaccines that could never pass FDA approval without an EUA, and then give them a boatload of money to make it happen.
And that’s what happened in July of 2020 when Trump’s Operation Warp Speed gave Novavax $1.6 BILLION, even though they had failed to produce a single vaccine for over 30 years.
Donald Trump was simply the puppet politician that rubber stamped all this, of course, as the real people who made all this happen were the Wall Street Mega Banks, led by Jamie Dimon and JPMorgan Chase, who bailed themselves out at the end of 2019 to create the cash that was going to be needed to do all this.
[…]
These investment firms, led by Vanguard and Blackrock, will now probably just sell most of their stocks in Pfizer, if they haven’t already, and simply move over to Novavax.
Here’s who owns Novavax according to the Wall Street Journal:
And why not? This playbook worked so well for Pfizer, raking in record profits, why not do it again for another company that cannot produce a vaccine that would pass FDA standards, by issuing an EUA and then targeting the population that has yet to get a COVID-19 vaccine, the “vaccine hesitant” and children.
Apparently, Novavax has a wide appeal for the ignorant masses who are being targeted by this new “educational program” who are eagerly awaiting Novavax to be given an EUA by the FDA so they can rush out and get it.
[…]